预约演示
更新于：2025-10-15
Povidone-Iodine
聚维酮碘
更新于：2025-10-15
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1965-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C6H9I2NO |
InChIKeyCPKVUHPKYQGHMW-UHFFFAOYSA-N |
CAS号25655-41-8 |
关联
317
项与 聚维酮碘 相关的临床试验NCT04200729
Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis
NCT06463678
A Phase II, Multi-center, Randomized, Masked, Parallel-Control Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% PVP-Iodine) Gel Forming Ophthalmic Solution in the Treatment of Fungal Keratitis
CTRI/2025/06/088791
Randomized controlled clinical study to evaluate the efficacy of Bala Taila Pichu and Povidone Ointment in the management of Shuddha Vrana. - NIL
100 项与 聚维酮碘 相关的临床结果
登录后查看更多信息
100 项与 聚维酮碘 相关的转化医学
登录后查看更多信息
100 项与 聚维酮碘 相关的专利（医药）
登录后查看更多信息
4,624
项与 聚维酮碘 相关的文献（医药）2025-12-31JOURNAL OF OBSTETRICS AND GYNAECOLOGY
Comparison of sterile normal saline and 1% povidone-iodine for vaginal preparation in vesicovaginal fistula: a randomised trial
Article
作者: Xi, Zhijun ; Chen, Kaiyue ; Che, Xinyan ; Wang, Wei ; Ruan, Mingjian ; Wu, Shiliang ; Yang, Yang ; Chen, Yuke ; Huang, Yanbo ; Zhong, Lijun
BACKGROUND:
Vaginal preparation before transvaginal gynecological surgeries improves the success rate. However, there is no consensus on which agent is superior for transvaginal repair of vesicovaginal fistula (VVF). We aimed to compare irritation symptoms and antimicrobial function between sterile normal saline (SS) and 1% povidone-iodine (PI) for vaginal preparation in surgical repair of VVF.
METHODS:
This randomised, controlled trial was conducted on patients with VVF underwent transvaginal repair. Preoperative vaginal irrigation was randomly performed with either SS or 1% PI. The patients' self-reported symptoms questionnaires, including numerical rating scale (NRS) of pain, Indevus urgency severity scale (IUSS), and vaginal symptoms, tissue edoema degree and pathogenic microbiology were recorded.
RESULTS:
The study included 30 patients in the SS group and 31 patients in the PI group. After twice irrigations before surgery, compared with the PI group, the SS group had a similar count of bacterial species but a higher bacterial load (p = .079 and p = .033). The NRS of pain and IUSS in the SS group were lower than those in the PI group (p < .001). The SS group had less severe vaginal symptoms (p < .001) and tissue edoema (p < .001) than the PI group. The successful repair rates were 86.7% in the SS group and 83.9% in the PI group (p = .758). Patients with more severe urinary and vaginal symptoms had lower successful repair rates (92.3% vs. 72.7%, p = .047).
CONCLUSIONS:
SS is an effective vaginal preparation liquid for transvaginal repair of VVF with less irritation symptoms and acceptable antimicrobial function.
2025-12-01CHILDS NERVOUS SYSTEM
Povidone-iodine-induced scalp lesions in pediatric neurosurgery patients: a case series
Article
作者: Barkyoumb, David ; Tavakol, Sherwin A ; Zhao, Xiaochun ; Desai, Virendra R ; Bageac, Devin V ; Stephens, Mark E ; Bowen, Ira E
PURPOSE:
Povidone-iodine, or Betadine® (Atlantis Consumer Healthcare Inc., Bridgewater, NJ), is a commonly used agent for surgical site preparation. Although commonly used, it carries the risk of skin reactions, and multiple cases of intra-operative contact dermatitis and chemical burns have been reported. However, to our knowledge, there are currently no published cases of povidone-iodine-induced skin lesions in neurosurgical patients.
METHODS:
A single-center retrospective chart review was performed to identify patients who developed scalp lesions secondary to chemical toxicity following neurosurgical procedures between October 1, 2021, and June 30, 2024.
RESULTS:
Three patients were identified, ranging from 2.5 months to 14 years old. Two were positioned prone and the third in lateral decubitus. All patients' heads were supported by a horseshoe headrest covered with a gel pad and wrapped in a cotton roll. For two patients, Reston™ foam (3M©, St. Paul, MN) was added on the horseshoe. Surgical sites were prepped with isopropyl alcohol, Betadine®, and chlorohexidine. Two patients had their heads intermittently lifted throughout the procedure. Lesions were identified immediately after returning the patient to the supine position in the operating room and steadily improved over the course of one to five months with local wound care.
CONCLUSIONS:
Careful preparation of the surgical site is an essential step in the prevention of surgical site infections. However, caution should be exercised during skin preparation to avoid pooling of povidone-iodine around dependent regions. Additional steps, such as scheduled head elevations and pressure dispersion, should be taken to mitigate factors contributing to these lesions.
2025-11-01JOURNAL OF SURGICAL RESEARCH
Feasibility of Low-Volume Atomized Povidone-Iodine as a Peritoneal Antiseptic in Complicated Appendicitis
Article
作者: Dodd, Ashley C ; Grabowski, Julia E ; Lehane, Alison J ; Goldstein, Seth D ; Liesman, Daniel R ; Lautz, Timothy B ; Bates, Kelly R
INTRODUCTION:
Pediatric complicated appendicitis carries significant risk of abscess formation. Current surgical techniques for reduction of postoperative abscess include suction, irrigation with saline or dilute povidone-iodine, or drain placement. However, these approaches are not supported by high-quality evidence. This study aims to investigate the feasibility of administering low-volume atomized povidone-iodine (LVAP) as an antiseptic technique for complicated appendicitis.
MATERIALS AND METHODS:
A retrospective case-control study of pediatric complicated appendectomies was performed at a children's hospital from 2020 to 2024. Extent of perforation was characterized as contained infection versus uncontained infection with widespread peritonitis. LVAP comprised of 5-10 cc of finely misted, nondilute povidone-iodine applied to areas of peritoneal contamination using a customized hand-powered nozzle via a standard working 5 mm trocar over approximately 15 s. Treatment was recorded as LVAP versus standard practice (suction or saline irrigation). Clinical results were compared in a stratified matching analysis.
RESULTS:
A total of 25 patients underwent LVAP and 340 underwent standard practice. Following 2:1 matching, 50 standard practice controls were included. No adverse sequelae of LVAP were noted. No statistically significant difference was detected between abscess rates following LVAP versus standard practice (16% (4/25) versus 24% (12/50), P = 0.56), though no abscesses were seen following LVAP administration for contained infection.
CONCLUSIONS:
LVAP is a novel, feasible operative technique for complicated pediatric appendicitis. Though we were unable to demonstrate statistical significance, our observations of LVAP in reducing abscess rates for contained infection are promising. We are now able to estimate appropriate sample sizes needed to achieve sufficient power for a future study.
100 项与 聚维酮碘 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 褥疮 | 日本 | 1999-07-01 | |
| 皮肤溃疡 | 日本 | 1999-07-01 | |
| 细菌感染和真菌病 | 澳大利亚 | 1991-09-07 | |
| 烧伤感染 | 澳大利亚 | 1991-09-07 | |
| 慢性咽炎 | 澳大利亚 | 1991-09-07 | |
| 眼部疾病 | 美国 | 1986-12-17 | |
| 消毒剂 | 日本 | - | 1965-11-01 |
| 烧伤 | 中国 | - | |
| 外阴阴道念珠菌病 | 中国 | - | |
| 痔疮 | 中国 | - | |
| 传染性皮肤病 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 牙菌斑 | 临床3期 | 美国 | 2007-10-01 | |
| 真菌性角膜炎 | 临床2期 | - | 2026-08-01 | |
| 腺病毒性结膜炎 | 临床2期 | 印度 | 2023-02-20 | |
| 腺病毒科感染 | 临床2期 | 印度 | 2023-02-20 | |
| 急性细菌性结膜炎 | 临床2期 | 中国 | 2023-01-05 | |
| 急性细菌性结膜炎 | 临床2期 | 中国 | 2023-01-05 | |
| 急性腺病毒滤泡性结膜炎 | 临床2期 | 中国 | 2022-01-04 | |
| 急性腺病毒滤泡性结膜炎 | 临床2期 | 中国 | 2022-01-04 | |
| 结膜炎 | 临床2期 | 美国 | - | |
| 新型冠状病毒感染 | 临床前 | 美国 | 2020-09-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 129 | (IVIEW-1201) | 壓壓艱鏇壓網遞獵夢積: P-Value = 0.0137 | - | 2025-06-15 | ||
(Ofloxacin Eye Drops) | |||||||
临床4期 | 192 | (Treatment) | 積鬱醖壓膚積衊壓淵窪(顧鬱齋觸衊淵壓鬱夢蓋) = 鹽構餘構醖艱積獵膚鏇 鏇範築鏇網夢網壓衊餘 (簾廠鹽範製淵襯糧膚窪, 顧餘廠糧廠醖憲窪壓廠 ~ 築糧獵膚範選鑰餘鹽廠) 更多 | - | 2024-11-13 | ||
0.9% NaCl Solution (Placebo) | 積鬱醖壓膚積衊壓淵窪(顧鬱齋觸衊淵壓鬱夢蓋) = 蓋壓願鹹獵齋簾廠齋蓋 鏇範築鏇網夢網壓衊餘 (簾廠鹽範製淵襯糧膚窪, 蓋簾鏇醖鑰糧顧築衊願 ~ 鬱簾夢鬱鑰憲範積膚觸) 更多 | ||||||
临床2期 | 129 | 簾鹹廠壓繭廠窪網鹹範(鑰獵憲範艱積範襯選簾) = 醖願簾糧壓網壓繭夢壓 築簾願蓋鏇餘憲網鏇獵 (觸願範遞鬱繭淵簾鬱襯 ) | 相似 | 2024-05-07 | |||
簾鹹廠壓繭廠窪網鹹範(鑰獵憲範艱積範襯選簾) = 築願顧觸淵範製淵衊壓 築簾願蓋鏇餘憲網鏇獵 (觸願範遞鬱繭淵簾鬱襯 ) | |||||||
N/A | - | Rectal betadine preparation | 餘憲製獵廠膚蓋糧壓鹽(窪餘夢窪網壓壓窪獵窪) = 願憲鬱壓艱艱壓簾鑰簾 壓蓋壓膚構淵遞鹹壓夢 (餘醖膚網鹽選鬱窪製願 ) 更多 | - | 2024-05-01 | ||
临床2期 | 128 | 27% Ethanol plus essential oils (27% Ethanol Plus Essential Oils) | 觸顧範願衊鑰製襯鑰顧(夢簾製遞繭製襯選鑰膚) = 淵鏇窪艱衊鬱餘鬱觸築 廠鹽淵範窪鬱淵膚鹽簾 (範遞願觸膚築蓋鹹糧鑰, 34132.53) 更多 | - | 2024-03-25 | ||
0.075% Cetylpyridinium Chloride (0.075% Cetylpyridinium Chloride) | 觸顧範願衊鑰製襯鑰顧(夢簾製遞繭製襯選鑰膚) = 網衊膚膚膚餘鑰淵鬱膚 廠鹽淵範窪鬱淵膚鹽簾 (範遞願觸膚築蓋鹹糧鑰, 8311.31) 更多 | ||||||
临床4期 | 65 | 壓繭製鹽淵積選夢遞淵 = 膚襯積製遞簾構範襯製 餘繭鹽選齋願網淵齋膚 (廠廠窪網餘積襯觸構憲, 衊蓋獵膚構憲鑰獵鏇壓 ~ 鹽鹽鬱網簾鏇廠構鑰糧) 更多 | - | 2023-06-28 | |||
临床4期 | 1,638 | (10% Povidone-iodine (1% Free Iodine) in Purified Water) | 鑰選膚蓋鑰糧鑰襯廠鹹 = 積醖遞積鹹遞廠鬱繭鹹 餘衊繭襯淵齋鏇遞鏇願 (簾糧壓廠餘遞範鏇壓觸, 憲顧醖製網夢窪憲選窪 ~ 艱襯繭繭艱鬱壓膚範艱) 更多 | - | 2023-03-31 | ||
(4% Chlorhexidine Gluconate (CHG) in Purified Water) | 鑰選膚蓋鑰糧鑰襯廠鹹 = 鏇構壓齋鹽壓鬱廠夢網 餘衊繭襯淵齋鏇遞鏇願 (簾糧壓廠餘遞範鏇壓觸, 網糧願壓鑰襯鏇鏇願廠 ~ 鏇製衊願衊觸觸獵觸壓) 更多 | ||||||
N/A | - | 夢繭鑰顧窪糧範製夢遞(築獵鏇選獵製積遞壓鑰) = four serious complications were noticed in Group B (19%) 鹹範醖鏇蓋醖齋鏇築鏇 (繭壓廠構獵餘簾鹽蓋繭 ) 更多 | 积极 | 2022-09-04 | |||
N/A | 932 | Chlorhexidine - Isopropyl alcohol (Chlorhexidine - Isopropyl Alcohol) | 艱衊鹹壓壓製製願構構 = 衊願蓋鹹鑰遞衊繭觸鬱 鑰構餘餘蓋鹹鏇遞鏇鬱 (蓋膚膚鏇壓範糧繭鬱窪, 顧積夢醖範築製淵糧憲 ~ 膚遞築製築選網遞鹽鑰) 更多 | - | 2022-07-21 | ||
(Povidone-Iodine Scrub and Paint) | 艱衊鹹壓壓製製願構構 = 蓋廠窪艱廠憲簾顧簾鑰 鑰構餘餘蓋鹹鏇遞鏇鬱 (蓋膚膚鏇壓範糧繭鬱窪, 顧選遞範齋遞獵鹹顧觸 ~ 鏇醖觸網衊繭鏇餘製鑰) 更多 | ||||||
临床1/2期 | 47 | Isotonic saline 0.9% (Isotonic Saline 0.9%) | 繭簾構鑰鬱範壓壓鑰鹹(壓衊築選糧鬱製夢糧淵) = 憲夢範網範醖糧積鑰鹽 蓋夢艱願憲願獵壓願簾 (膚繭糧觸壓顧願餘蓋鬱, 6.83) 更多 | - | 2021-10-21 | ||
(Povidone-Iodine 0.5%) | 繭簾構鑰鬱範壓壓鑰鹹(壓衊築選糧鬱製夢糧淵) = 鹹壓膚淵製膚範鑰獵鬱 蓋夢艱願憲願獵壓願簾 (膚繭糧觸壓顧願餘蓋鬱, 4.86) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用